BioSpace News Archive

The Diabetes Research Institute, a world leader focused on finding a cure for type 1 diabetes, recently announced the appointment of its new scientific director, Matthias von Herrath, M.D.

BioAegis Therapeutics, Inc. announces that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for recombinant plasma gelsolin to proceed for the treatment of acute respiratory distress syndrome (ARDS).

Livanta LLC (“Livanta”) has announced that it has successfully achieved Capability Maturity Model Integration Development (CMMI-DEV) V2.0 Maturity Level 3 certification.

invoX Pharma, a wholly owned subsidiary of Sino Biopharmaceutical Limited, and F-star Therapeutics, Inc., issued the following statement regarding their pending transaction in response to a media report:

Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that its board of directors has appointed a new independent director, Jill DeSimone, who will join effective March 1, 2023.

ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2022.

Penumbra, Inc. (NYSE: PEN) today announced that it will host a conference call to discuss financial results for the fourth quarter and full year 2022 after market close on Thursday, February 23, 2023 at 4:30 PM Eastern Time.

Tonix Pharmaceuticals Holding Corp. announced that Tom Hobman, Ph.D., Professor of Cell Biology, University of Alberta, presented data from his laboratory at The University of Alberta during a presentation at the 2nd Wnt & β-catenin Targeted Drug Development Conference held in Boston, Mass., on January 26, 2023.

Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) today announced Anatoly Dritschilo, M.D., CEO, will present and host one-on-one meetings with investors at the Lytham Partners Investor Select Conference, taking place virtually on January 31, 2023.

Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) (“Hemostemix” or the “Company”) is pleased to announce the Japan Patent Office issued Kwalata Trading Limited, a wholly owned subsidiary of Hemostemix Inc., a trademark registration certificate for Your Fountain of Youth.